biostudies-literatureUnknown175(2)Blobner JUniversitätsklinikum Erlangen<h4>Background</h4>The 2021 WHO classification of CNS tumors allows flexibility in the grading of IDH-mutant astrocytic gliomas, leading to some ambiguity. Following the approval of vorasidenib for WHO grade 2 astrocytomas and oligodendrogliomas based on the positive Phase III INDIGO trial, identifying prognostic criteria to differentiate between grade 2 and grade 3 tumors has become increasingly important.<h4>Methods</h4>We retrospectively searched our institutional database for patients meeting the diagnostic criteria for IDH-mutant astrocytomas (grade 2 and 3) according to the WHO 2021 classification. Clinical, radiological and molecular data were collected; outcome was compared using log-rank analysis and prognostic markers were subsequently forwarded in a multivariate model.<h4>ResultJournal of neuro-oncology763-774https://www.ebi.ac.uk/biostudies/studies/S-EPMC12420753biostudies-literatureClinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3.PMC12420753Teske NRuf VRingel FThon NSchoenecker SBlobner JTonn JCWeller JKarschnia Pvon Baumgarten LForbrig RAlbert NLHarter PNfalseClinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3.<h4>Background</h4>The 2021 WHO classification of CNS tumors allows flexibility in the grading of IDH-mutant astrocytic gliomas, leading to some ambiguity. Following the approval of vorasidenib for WHO grade 2 astrocytomas and oligodendrogliomas based on the positive Phase III INDIGO trial, identifying prognostic criteria to differentiate between grade 2 and grade 3 tumors has become increasingly important.<h4>Methods</h4>We retrospectively searched our institutional database for patients meeting the diagnostic criteria for IDH-mutant astrocytomas (grade 2 and 3) according to the WHO 2021 classification. Clinical, radiological and molecular data were collected; outcome was compared using log-rank analysis and prognostic markers were subsequently forwarded in a multivariate model.<h4>Result2025-01-01T00:00:00Z2025 Nov2026-06-01T13:55:51.805Z2026-04-08T13:11:52.551ZS-EPMC124207534070238710.1007/s11060-025-05173-z